Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Pinealon vs Semax
An educational, source-based comparison of Pinealon and Semax — how each peptide works, what it's researched for, and what to know before going deeper.
Short peptide bioregulator researched for cognition and aging.
A synthetic tripeptide (Glu-Asp-Arg) in the Khavinson short-peptide bioregulator family. Research from Russian gerontology groups proposes gene-expression modulation linked to neuronal survival and cognitive performance.
- Cognitive aging in rodent models
- Neuronal apoptosis under oxidative stress
- Circadian and neuroendocrine regulation
- • Most evidence from Russian literature; independent replication is limited.
- • Not FDA-approved.
A synthetic heptapeptide derived from ACTH(4-10). Research suggests it modulates BDNF and NGF expression, dopaminergic and serotonergic tone, and shows neuroprotective effects in ischemia models.
- BDNF/NGF upregulation
- Ischemic stroke recovery (clinical use in Russia)
- Attention and cognitive performance
- Anxiolytic-style effects
- • Approved as a medication in Russia; not FDA-approved in the US.
- • Most clinical literature is in Russian.
Pinealon vs Semax — Key differences
- Class: Pinealon is classified as Bioregulator · Neuroprotection, while Semax is Nootropic · Neuroprotection.
- Primary research focus: Pinealon — cognitive aging in rodent models; Semax — bdnf/ngf upregulation.
- Tag: Cognition · Longevity vs Cognition.